Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)

14 septembre 2026 mis à jour par: InSilico Medicine Hong Kong Limited

A Prospective Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Safety of Rentosertib (INS018_055) Administered Orally Over 52 Weeks in Patients With Idiopathic Pulmonary Fibrosis (IPF)

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Rentosertib (INS018_055) administered orally in Patients with Idiopathic Pulmonary Fibrosis.

The purpose of this study is to evaluate if Rentosertib (INS018_055) works to treat patients with Idiopathic Pulmonary Fibrosis in adults. It will also learn about the safety of Rentosertib (INS018_055).

In this study, Rentosertib (INS018_055) will be compared to a placebo (a look-alike substance that contains no drug) to investigate if Rentosertib (INS018_055) works to treat Idiopathic Pulmonary Fibrosis.

Aperçu de l'étude

Statut

Recrutement

Type d'étude

Interventionnel

Inscription (Estimé)

320

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Anhui
      • Hefei, Anhui, Chine
        • Pas encore de recrutement
        • Anhui Provincial Hospital
      • Hefei, Anhui, Chine
        • Pas encore de recrutement
        • Anhui Chest Hospital
    • Beijing Municipality
      • Beijing, Beijing Municipality, Chine
        • Recrutement
        • Peking Union Medical College Hospital
      • Beijing, Beijing Municipality, Chine
        • Recrutement
        • Beijing Friendship hospital, Capital Medical University
      • Beijing, Beijing Municipality, Chine
        • Pas encore de recrutement
        • Beijing Chaoyang Hospital, Capital Medical University
    • Fujian
      • Fuzhou, Fujian, Chine
        • Pas encore de recrutement
        • Fuzhou University Affiliated Provincial Hospital
      • Xiamen, Fujian, Chine
        • Recrutement
        • The Second Affiliated Hospital of Xiamen Medical College
    • Guangdong
      • Guangzhou, Guangdong, Chine
        • Recrutement
        • The First Affiliated Hospital of Guangzhou Medical University
      • Guangzhou, Guangdong, Chine
        • Pas encore de recrutement
        • Nanfang Hospital, Southern Medical University
    • Guangxi
      • Nanning, Guangxi, Chine
        • Pas encore de recrutement
        • The First Affiliated Hospital of Guangxi Medical University
    • Hainan
      • Haikou, Hainan, Chine
        • Recrutement
        • Hainan General Hospital
    • Hebei
      • Shijiazhuang, Hebei, Chine
        • Pas encore de recrutement
        • The Second Hospital of Hebei Medical University
      • Shijiazhuang, Hebei, Chine
        • Pas encore de recrutement
        • Hebei Medical University Third Hospital
    • Henan
      • Anyang, Henan, Chine
        • Recrutement
        • The People's Hospital of Anyang City
      • Nanyang, Henan, Chine
        • Recrutement
        • Nanyang First People's Hospital
      • Zhengzhou, Henan, Chine
        • Pas encore de recrutement
        • Henan Provincial People's Hospital
      • Zhengzhou, Henan, Chine
        • Pas encore de recrutement
        • The First Affiliated Hospital of Zhengzhou University
    • Hubei
      • Wuhan, Hubei, Chine
        • Pas encore de recrutement
        • Renmin Hospital of Wuhan University
      • Wuhan, Hubei, Chine
        • Pas encore de recrutement
        • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
      • Yichang, Hubei, Chine
        • Pas encore de recrutement
        • Yichang Central People's Hospital
    • Hunan
      • Changsha, Hunan, Chine
        • Pas encore de recrutement
        • The Second Xiangya Hospital of Central South University
      • Changsha, Hunan, Chine
        • Pas encore de recrutement
        • The Xiangya Hospital of Central South University
    • Inner Mongolia
      • Hohhot, Inner Mongolia, Chine
        • Pas encore de recrutement
        • The Affiliated Hospital of Inner Mongolia Medical University
    • Jiangsu
      • Nanjing, Jiangsu, Chine
        • Recrutement
        • Nanjing Drum Tower Hospital
      • Xuzhou, Jiangsu, Chine
        • Pas encore de recrutement
        • The Affiliated Hospital of Xuzhou Medical University
    • Jiangxi
      • Nanchang, Jiangxi, Chine
        • Pas encore de recrutement
        • Jiangxi Provincial People' Hospital
    • Jilin
      • Changchun, Jilin, Chine
        • Pas encore de recrutement
        • The Second Hospital of Jilin University
    • Liaoning
      • Shenyang, Liaoning, Chine
        • Pas encore de recrutement
        • Shengjing Hospital of China Medical University
    • Shaanxi
      • Xi'an, Shaanxi, Chine
        • Recrutement
        • The Second Affiliated Hospital of Xi'an Jiaotong University
      • Xi'an, Shaanxi, Chine
        • Recrutement
        • The First Affiliated Hospital of Xi'an Medical College
    • Shandong
      • Jinan, Shandong, Chine
        • Pas encore de recrutement
        • Qilu Hospital of Shandong University
      • Jinan, Shandong, Chine
        • Pas encore de recrutement
        • Introduction of the First Affiliated Hospital of Shandong First Medical University
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Chine
        • Recrutement
        • Shanghai Pulmonary Hospital Affiliated to Tongji University
    • Shanxi
      • Taiyuan, Shanxi, Chine
        • Pas encore de recrutement
        • Shanxi Bethune Hospital
      • Yuncheng, Shanxi, Chine
        • Pas encore de recrutement
        • Yuncheng Central Hospital
    • Sichuan
      • Chengdu, Sichuan, Chine
        • Pas encore de recrutement
        • West China Hospital, Sichuan University
      • Chengdu, Sichuan, Chine
        • Pas encore de recrutement
        • Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Chine
        • Pas encore de recrutement
        • Tianjin Medical University General Hospital
      • Tianjin, Tianjin Municipality, Chine
        • Pas encore de recrutement
        • Tianjin Chest Hospital
    • Xinjiang
      • Ürümqi, Xinjiang, Chine
        • Pas encore de recrutement
        • The First Affiliated Hospital of Xinjiang Medical University
    • Yunnan
      • Kunming, Yunnan, Chine
        • Pas encore de recrutement
        • The First People Hospital of Yunnan Province
    • Zhejiang
      • Hangzhou, Zhejiang, Chine
        • Pas encore de recrutement
        • Sir Run Run Shaw Hospital Zhejiang University School of Medicine
      • Hangzhou, Zhejiang, Chine
        • Recrutement
        • Affiliated Hangzhou First People's Hospital,School of Medicine, Westlake University
      • Jiaxing, Zhejiang, Chine
        • Pas encore de recrutement
        • The First Hospital of Jiaxing
      • Ningbo, Zhejiang, Chine
        • Pas encore de recrutement
        • Ningbo Medical Center Lihuili Hospital
      • Ningbo, Zhejiang, Chine
        • Pas encore de recrutement
        • The First Affiliated Hospital of Ningbo University
      • Wenzhou, Zhejiang, Chine
        • Pas encore de recrutement
        • The First Affiliated Hospital of Wenzhou Medical University

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

La description

Inclusion Criteria:

  1. An informed consent form (ICF) signed and dated at screening (Visit 1), prior to initiation of any study related procedures, and in accordance with ICH-GCP and local legislation.
  2. Patients aged ≥40 years at time of signing the ICF.
  3. Diagnosis of IPF based on the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guideline, confirmed by an HRCT chest scan within 3 months prior to screening visit.
  4. UIP or probable UIP with fibrosis extent >10% at HRCT.
  5. Meet all the following criteria during the screening period:

    1. FVC ≥45% predicted of normal
    2. FEV1/FVC ≥0.7
    3. DLCO (corrected for hemoglobin) ≥25% and <80% predicted of normal.
  6. Background antifibrotic therapies are allowed, patients may be either:

    1. on a stable therapy with nintedanib or pirfenidone as monotherapy for at least 12 weeks prior to screening visit and during the screening period and are planning to stay on this background treatment after randomization.
    2. not on a treatment with nintedanib or pirfenidone for at least 8 weeks prior to screening visit and during the screening period and do not plan to start or restart antifibrotic therapy.
  7. Estimated minimum life expectancy of at least 30 months for non-IPF related disease in the opinion of the investigator.
  8. Male patients and female patients of childbearing potential agree to use highly effective contraception/preventive exposure measures from the time of the first dose of the study drug (for the male patient) or the signing of the ICF (for the female patient) until 90 days after the last dose of the study drug.

Exclusion criteria:

  1. Interstitial lung disease associated with known primary diseases (eg, autoimmune disease-related interstitial lung diseases, sarcoidosis and amyloidosis), exposures (eg, radiation, silica, asbestos, and coal dust), or drugs (eg, amiodarone).
  2. Previous participation in a clinical study with rentosertib (active or placebo).
  3. Concurrent participation in another interventional drug, device, or biological investigational research study, or use of an investigational agent within 5 half-lives of the agent (or within 8 weeks when half-life is unknown) prior to screening is not allowed.
  4. Pulmonary hypertension that is clinically relevant or severe as deemed by the investigator, or other clinically significant pulmonary abnormalities.
  5. Unstable cardiovascular or other disease within 6 months prior to the screening visit or during the screening period.
  6. Presence of other clinically significant airway disease that may, in the opinion of the investigator, impact the study safety or efficacy objectives, such as asthma, bronchiectasis, cystic fibrosis, active aspergillosis, active tuberculosis, or other serious concomitant respiratory disorder other than pulmonary fibrosis.
  7. Acute exacerbation of IPF within 6 months prior to screening visit and/or during the screening period.
  8. Patients with underlying chronic liver disease (Child Pugh A, B, or C hepatic impairment), hepatic steatosis (including non-alcoholic steatohepatitis and/or other types of fatty liver diseases).
  9. Patients with Gilbert's disease
  10. Relevant chronic or acute infections including human immunodeficiency virus (HIV) and clinically significant viral hepatitis.
  11. Aspartate aminotransferase or alanine aminotransferase ≥1.5 × upper limit of normal (ULN), and/or total bilirubin ≥1.5 × ULN, and/or gamma glutamyl transferase ≥3 × ULN, and/or alkaline phosphatase ≥1.5 × ULN at screening.
  12. Estimated glomerular filtration rate <60 mL/min/1.73m2 at screening.
  13. Patient with 12-lead ECG demonstrating corrected QT interval by Fridericia (QTcF) >450 ms for males and >470 ms for females at screening (Visit 1).
  14. Patient with a history of lung volume reduction surgery or lung transplant.
  15. Current smoker and/or cotinine (smoking) test positive.
  16. History of drug abuse, drug use, or alcohol abuse within the past 3 months.
  17. Major surgery performed within 3 months prior to screening visit, during the screening period, or have major surgery planned during the study period.
  18. Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening visit.
  19. Use of any of the following therapies within 4 weeks prior to screening visit and during the screening period or planned during the study: warfarin and immunosuppressive medications.
  20. Patients currently taking endothelin receptor antagonists,phosphodiesterase type 5 inhibitors, soluble guanylate cyclase modulators, prostacyclin analogues and prostanoids, or activin signaling inhibitor.
  21. Patients currently on a treatment with nerandomilast within 8 weeks prior to screening visit and during the screening period.
  22. Use of any of the following drugs within 2 weeks prior to Visit 1/screening or planned during the duration of the study

    1. Strong and moderate cytochrome P450 3A4 or 1A2 inhibitors/inducers
    2. Medications associated with substantial risk for prolongation of corrected QT interval.
  23. Patients who have consumed grapefruit or grapefruit juice, pomelo, Seville orange or Seville orange-containing products within 48 hours before Day 1.
  24. Patients who used hormone replacement therapy in the 4 weeks prior to randomization. No hormone replacement therapy use is allowed during the study.
  25. Patients with known hypersensitivity or contraindications to serine/threonine kinase inhibitors.
  26. Any condition that would interfere with the interpretation of study assessments or impair study participation.
  27. Any physical or psychological conditions or circumstance that, in the opinion of the investigator, may make a patient unsuitable for inclusion or unlikely or unable to complete the study or comply with study procedures and requirements.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Active
Patients assigned will receive ISN018_055 tablets orally QD for 52 weeks
Dosage form: Tablets; Frequency of administration: Orally QD. Other Names: Rentosertib
Comparateur placebo: Placebo
Patients assigned will receive matching placebo orally QD for 52 weeks
Forme galénique: Comprimé; Fréquence d'administration: Par voie orale QD.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Délai
the annual rate of forced vital capacity (FVC; mL) decline over 52 weeks.
Délai: Weeks 0,4,12,26,39,52
Weeks 0,4,12,26,39,52

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
time to first occurrence of any disease progression
Délai: up to 52 weeks
including 1) percent predicted forced vital capacity decrease relative to baseline greater than 10%, 2) acute exacerbation of IPF, 3) respiratory-related hospitalization, or 4) death due to respiratory
up to 52 weeks
change from baseline to Week 52 in quantitative computed tomography-derived lung fibrosis burden on high-resolution computed tomography(HRCT)
Délai: week 52
week 52
change from baseline in quality of life (QoL) as measured by the patient-reported outcomes questionnaires using King's Brief Interstitial Lung Disease questionnaire (K BILD)
Délai: Weeks 0,4,12,26,39,52
Weeks 0,4,12,26,39,52
change from baseline in QoL as measured by the patient-reported outcomes questionnaires using Living with Pulmonary Fibrosis(L-PF)
Délai: Weeks 0,4,12,26,39,52
Weeks 0,4,12,26,39,52
change from baseline in hemoglobin-corrected diffusing capacity of the lung for carbon monoxide (DLCO) over 52 weeks
Délai: Weeks 0, 52
Weeks 0, 52

Autres mesures de résultats

Mesure des résultats
Délai
Incidence of treatment-emergent adverse events(Safety and Tolerability), and clinically significant changes in physical examination,vital signs,safety laboratory test
Délai: up to 56 weeks
up to 56 weeks
Clinically significant changes in the 12-lead electrocardiogram(ECG) of ECG QTcF Interval
Délai: Weeks 0,2,4,8,12,26,39,52
Weeks 0,2,4,8,12,26,39,52
Clinically significant changes in the 12-lead electrocardiogram(ECG) of ECG Heart Rate
Délai: Weeks 0,2,4,8,12,26,39,52
Weeks 0,2,4,8,12,26,39,52
changes from baseline in serum proteome by high throughput proteomic analysis at Weeks 12, 26, and 52
Délai: weeks 0, 12 ,26, and 52
weeks 0, 12 ,26, and 52
changes from baseline in serum bone biomarker of procollagen 1 intact N-terminal propeptide [P1NP]
Délai: weeks 0, 52
weeks 0, 52
changes from baseline in serum bone biomarker of C-terminal telopeptide [CTX]
Délai: weeks 0, 52
weeks 0, 52

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

9 septembre 2026

Achèvement primaire (Estimé)

30 octobre 2029

Achèvement de l'étude (Estimé)

30 octobre 2029

Dates d'inscription aux études

Première soumission

22 juin 2026

Première soumission répondant aux critères de contrôle qualité

1 juillet 2026

Première publication (Réel)

7 juillet 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

17 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

14 septembre 2026

Dernière vérification

1 juin 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner